Nintedanib Teva

Nintedanib, the active ingredient in Nintedanib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain cases of non‑small cell lung cancer.

GNH USA supplies Nintedanib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable global logistics and timely delivery.

Nintedanib is used to treat fibrotic lung diseases and certain cancers by targeting pathways that drive fibroblast activity and tumor angiogenesis.

Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. Systemic sclerosis‑associated interstitial lung disease: improves pulmonary outcomes and delays worsening of lung capacity. Non‑small cell lung cancer (in specific settings): inhibits tumor growth and angiogenesis as part of combination therapy.

Nintedanib may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may occur with or without vomiting. - Abdominal pain: discomfort or cramps in the stomach area. - Elevated liver enzymes: increase in ALT/AST detected in blood tests.

Serious or Rare Side Effects: - Hepatotoxicity: severe liver injury, jaundice or hepatitis. - Bleeding events: gastrointestinal or other bleeding, especially with anticoagulants. - Cardiovascular events: arterial thromboembolism or myocardial infarction.

When prescribing Nintedanib, clinicians should consider several safety and handling precautions. - Liver function monitoring: assess baseline ALT/AST and repeat regularly during therapy. - Gastrointestinal management: advise patients to stay hydrated and report severe diarrhea. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors unless dose adjusted. - Bleeding risk: evaluate bleeding history and use caution with anticoagulants or antiplatelet agents. - Pregnancy and lactation: contraindicated or not recommended due to unknown fetal risk; avoid use in pregnant or nursing women. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Nintedanib can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding. - P‑glycoprotein inhibitors (e.g., verapamil): can raise plasma levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly increase exposure. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Antifungal azoles and certain antibiotics: require monitoring of liver enzymes.